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INTRODUCTION
Allergen extracts are indispensable for the diagnosis and 
treatment of allergic diseases. However, the quality of 
allergen extracts is affected by various factors because 
the extracts are biological products. Therefore, in order 
to raise the credibility of diagnosis and the effectiveness 
of treatment and to ensure safety in clinical use, it is nec-
essary to use standardized allergens.1-3 In Europe and the 
United States, the necessity of standardization has been 
recognized and clinically important allergens have been 
standardized and are commercially available. However, 
in our country, standardizations have not been per-
formed. For these reasons, in order to promptly discuss 
allergen standardization, the Japanese Society of Aller-
gology organized a Committee of Allergen Standardi-
zation. The committee, at first, determined essential 
guidelines for allergen standardization. In addition, the 
committee picked cedar pollen as the first target for study 
and performed selection of its standardized extracts and 
standardization, as cedar pollen is one of the most 
important allergens in Japan and the quality of its extracts 
is thought to cause several problems.
METHODS 
Can idates for standards of cedar pollen 
extracts
Eight lots of cedar pollen extract were supplied by the 
Torii Pharmaceutical Company Ltd, Tokyo, Japan. These 
extracts were prepared as follows. Fifty per cent glycerin-
NaCl solution (glycerin 50%, NaCl 5%) was added to 
dried pollen powder at a ratio of 20:1 (w/v) and was
mixed and stirred with ceramic balls for 24h at 5℃; the
mixture was then centrifuged and the supernatant was 
sterilized by filtration. An extract of Japanese cedar pollen 
was obtained from the Hollister-Stier Company Ltd, 
Spokane, WA, USA, through the Committee of Antigen in 
the Japanese Allergy Association. This extract contained 
50% (w/v) glycerin solution, but the procedure by which 
the extract was prepared is not known.
Evaluation of the quality of pollen extracts
The quality of candidates for standardized cedar pollen 
extract was evaluated as follows: (i) observation of char-
acteristics and measurement of pH; (ii) existence of cedar 
pollen antigen by the double gel diffusion test; (iii) exis-
tence of amino residue by the ninhydrin test; (iv) existence 
of glycerin; (v) measurement of the spectrum that absorbs 
an ultraviolet beam; (vi) measurement of the fluorescent 
spectrum; and (vii) isoelectrical electrophoresis.
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 These tests were performed by the Common Rule 
and Common Examination Rule of the Department of 
Pharmacology, Japanese Government, and also by its 
standardized guidelines for biological products.
Measurement of Cry j 1 and Cry j 2 in pollen 
extracts
Cry j 1 was measured by enzyme-linked immunosorbent 
assay (ELISA) using monoclonal antibodies by the Japan-
ese National Institute for Health, National Sagamihara 
Hospital and by the Torii Pharmaceutical Company Ltd.4,5 
Cry j 2 was measured by ELISA using monoclonal anti-
bodies by the Japanese National Institute of Health and 
by the Torii Pharmaceutical Company Ltd.
Measurement of total allergenic activities by 
BAST inhibition test or ELISA inhibition test
The total allergenic activities of cedar pollen extracts were 
measured by the BAST inhibition test6 or by the ELISA inhi-
bition test.7 Sera were obtained from 30 patients who 
showed a score over 4 in cedar-pollen RAST and had not 
received immunotherapy with this allergen. Sera were 
pooled and were used for the inhibition test. The activity 
of each extract was determined by the FDA method8 using 
analysis of counts obtained. The BAST inhibition test was 
performed by the National Sagamihara Hospital and the 
ELISA inhibition test was performed by the Torii 
Pharmaceutical Company Ltd.
Measurement of activities by skin test
Measurement of activities by skin test was performed by 
the method of the FDA (USA)9 with some modifications, 
most notably the determination of the endpoint. In the 
FDA method, a degree of extract dilution, which results in 
a total 50mm flare of shorter diameter plus longer diam-
eter, is determined from a regression line and patients are 
selected as the slope of the line is equal to 
or greater than 10mm and the correlation efficient is 
greater than 0.85, when over three concentrations were
applied. In contrast, in our method, the endpoint was 
determined by Ishizaki's criteria,10 where the skin reaction 
is regarded as positive if the diameter of the wheal is 
equal to or greater than 9mm and/or the diameter of the 
flare is equal to or greater than 20mm, by measuring the 
wheal and flare, although serial three-fold dilutions were 
similarly applied. The concepts of the two methods are
completely different. Another point at which our method 
differs to that of the FDA method is as follows. In our 
method 0.02mL extract was injected intradermally into 
an upper arm, whereas in the FDA method 0.05mL 
extract is injected intradermally into the back. It can be 
assumed that this difference does not affect the final 
results. With regard to the determination of activity, if a 
patient's endpoint occurs at a 310 dilution, the endpoint is 
assigned as 10 and the mean endpoint is calculated for 
all patients. In the FDA method, if the endpoint (E) is
equal to or greater than 9 and less than 11 (9≦E<11),
the titaer of the extract is assigned 1000 Allergy Units
(AU)/mL. If the titer is 11≦E<13 and 13≦E<15, the titer
is assigned as 10000 and 100000AU/mL, respectively. 
 Therefore, the same titer is assigned to extracts of, at 
most, 32; that is, an approximate 10-fold difference. Skin 
tests according to the FDA method were performed in 50 
adults (15-50 years old), who showed BAST scores over 
2, in six clinics (Japan Clinical Allergy Research Institute; 
Department of Otorhinolaryngology, School of Medicine, 
Chiba University; Department of Otorhinolaryngology, 
Dokkyo Medical School; Department of Otorhinolaryng-
ology, Second Hospital, Japanese Medical University; 
Department of Allergology, National Sagamihara Hos-
pital). However, patients who were receiving systemic 
steroid therapy, hyposensitization or antihistamine ther-
apy, or who were pregnant or had atopic skin at the test 
region were excluded as test subjects. In addition, the skin 
prick test according to Nordic guidelines11 was performed 
in 20 children in the National Children's Hospital.
RESULTS
At fir t, it was determined that the standardization of the 
allergen extract should be done as follows: 
(1) Select allergen extracts that can be standards. These 
standards should be representatives of extracts that are 
cli ically and routinely used. 
(2) Assign titers of standard extracts on the basis of skin 
tests that have been performed according to certain pro-
cedural rules. A titer common in all allergen extracts 
should be used.
(3) Evalute in vitro determination of titers (RAST inhibition 
t st, measurement of major allergen etc.) and examine 
whet r these methods can supply correct titers that 
reflect genuine biologic activities of the extracts. 
(4) Estimate the titer of commercially obtained extracts by 
certain in vitro methods. If the titer is consistent with that
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of the standard extract, within an acceptable range, the 
titer of the tested extract can be labeled as equal to the 
standard. This means that the titer of standard extracts is 
determined by a skin test and, thereafter, is maintained 
and managed by in vitro methods in place of skin tests.
Standardization of cedar pollen extract
The standardization of cedar pollen extracts was per-
formed according to the policy of allergen extract stan-
dardization mentioned above.
Selection of standard cedar pollen extracts
Eight batches of cedar pollen extracts were supplied by 
the Torii Pharmaceutical Company Ltd as candidates for 
standard extracts and their qualities were examined from 
various viewpoints. There were no problems in the analy-
sis of physicochemical and immunochemical characteris-
tics as described in Methods. Furthermore, similar results 
were obtained for all extracts. It was revealed by mea-
surement of Cry i 1 and Cry i 2 that Cry i 1 and Cry i 2 
were both found in all extracts. The difference in the con-
centration of these components between extract batches 
was, at most approximately two-fold, and the ratio of Cry 
j 1 and Cry j 2 was found to be approximately 1:1. With 
regard to the relative allergenic activity of each batch, as 
determined by the RAST inhibition test or by the ELISA 
inhibition test, the difference in activity between batches 
was; at most, approximately 2-fold, as was the concen-
tration of Cry j 1 or Cry j 2. Furthermore, the correlation 
coefficient between the relative activities and the concen-
trations of Cry j in these lots was 0.771, while that 
between the relative activities and the total concentration 
of Cry j 1 plus Cry j 2 was 0.931. Thus, good positive 
correlations were observed. The stability of the extracts 
and the effects of freezing and thawing on the extracts 
was also examined. It was revealed that the extracts were 
very stable, did not lose activity if frozen at temperatures
less than -55℃ and that there was no change in activity
even after freezing and thawing was repeated 10 times. 
As mentioned, it was confirmed by in vitro tests that there 
was no problem with the quality of eight batches of 
extracts supplied by the Torii Pharmaceutical Company 
Ltd and this was further confirmed by the skin test, as 
described below. All extracts had adequate activity. 
Therefore, one batch, called lot G, which had activity 
close to the mean activity, was selected as the standard 
cedar pollen extract in our country.
Determination of titers by the skin test
In the skin test, three types of cedar pollen extracts were 
used: (i) a standard cedar pollen extract (batch C); (ii) a 
five-fold diluted extract that was prepared quite similarly 
to the batch in (i), but which is from a different batch; and 
(iii) an extract from the Hollister-Stier Company Ltd, USA.
 The reason for using three different extracts was not 
only for the determination of the titer of the standard 
extract, but also for the examination of the correlation 
between the titer as determined by in vitro methods and 
by the skin test. The results from skin tests in 35 of 50 
patients were selected. The data from 15 patients were 
eliminated because they showed a positive reaction to a 
control solution or demonstrated an irregular relationship
between the concentration of extract and the size of the 
reaction, resulting in a difficulty in the determination of 
the endpoint. As shown in Table 1, the mean values for 
the endpoint determined by the intradermal skin test were 
12.9 in (i), 12.4 in (ii) and 12.7 in (iii). The relative activ-
ity of the three extracts was 312.9:3'2.4 :3127=1:0.58:0.80. 
In contrast, the relative activity of (i), (ii) and (iii) extracts 
as determined by the skin prick test in 16 eligible patients 
was 1:0.55:0.79 (Table 1).
Determination of titer by in vitro tests
The titers of the three types of extracts, (i), (ii) and (iii), 
were determined by three types of tests, namely the mea-
surement of Cry j 1 by ELISA, the measurement of Cry j 2 
by ELISA and the measurement of total allergenic activi-
ties by the RAST inhibition test or by the ELISA inhibition 
test. The data of total allergenic activity was analyzed 
according to the methods of the FDA.8
 It was revealed that the original data and all steps for 
obtaining relative activities were matched to all the statis-
cal rules. The final results are shown in Table 2. Because 
the total allergenic activities can not be presented as
Table 1. Comparison of allergenic potency of three Japanese 
cedar pollen extracts by intradermal and skin prick tests
  Values in parentheses are the potency ratios of test extracts relative 
to extract A.
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Table 2. Determination of allergenic potency of three 
Japanese cedar pollen extracts by in vitro assays
  Values in parentheses are the potency ratios of test extracts relative 
to extract A.
absolute amounts, only the relative activities are shown. 
As shown in Table 2, a good consistency was observed 
among the relative activities determined by the three 
tests. Although measurement of Cry j 1 and Cry j 2 does 
not detect the reactivity of the allergen (i. e. the reactivity 
of IgE antibodies), the amount of Cry j 1 or Cry j 2 in the 
extract had a good correlation with the total allergenic
activity determined by the RAST inhibition or ELISA inhibi-
tion tests. Furthermore, good reproducibility of results 
was observed between three laboratories, the variant 
coefficients of data in the three laboratories being 7.7% 
for (i), 12.4% for (ii) and 2.7% for (iii). These are within 
satisfactory limits.
Determination of a unit of titer in the standard cedar 
pollen extract and standardization of the in vitro 
titration method
The mean threshold of standard extract determined by 
the intradermal skin test was 12.7, which is over 11 and 
under 13. Therefore, the titer is 10000AU/mL if deter-
mined according to the FDA method. However, the 
method of skin test used is not completely the same as the 
FDA method. Therefore, Japanese Allergy Units (JAU) 
were introduced as a unique unit in our country and the 
calculation of the titer was performed according to the
FDA method. By using this method the titer of the stan-
dard extract was officially determined as 10000JAU/mL. 
Next, after the titer of the standard extract has been deter-
mined by the skin test, titers of commercially available 
cedar pollen extract can be maintained and managed by 
in vitro tests. For this, the measurement of Cry j 1 was 
used. The amount of Cry j 1 in the standard extract was
13.1, 11.7 and 13.7μg/mL when determined in three
loboratories. The committee considered that the extract
contained 12.5ｵ,g/mL of Cry j 1,which is close to the
mean value of the data from the three laboratories.
Thereafter, a cedar pollen extract can be labeled as hav-
ing a titer of 10000JAU/mL if it contains a similar 
amount of Cry j 1 with any difference within the accept-
able range. The committee determined that the accept-
able range should be 7.3-21μg/mL;that is, a three-fold
difference of approximately 12.5μg/mL. To summarize,
the Allergen Committee of the Japanese Society of 
Allergology made the following decisions regarding the 
standardization of Japanese cedar pollen extract:
(1) Japanese cedar pollen extract, Lot G (prepared by 
Torii Pharmaceutical Company Ltd), was determined to 
be the Japanese standard cedar pollen extract. 
(2) The titer of the standard extract was determined to be 
10000JAU/mL.
(3) The concentration of Cry j 1 in the standard extract
was determined to be 12.5μg/mL.
(4) When the concentration of Cry j 1 is within the range
7.3-21μg/mL in an extract, the titer of that extract can
be labelled as 10000JAU/mL.
DISCUSSION
For the standardization of allergen extracts, the most 
important step is the selection of a standard allergen 
extract. International standards for allergens important 
worldwide, such as Dermatophagoides pteronyssinus, 
timothy pollen and ragweed pollen, have already been 
selected. However, a standard extract for Japanese cedar 
pollen should be selected from Japan, because the tree is 
peculiar to this country. It is desirable that the standard
allergen extract is representative of extracts routinely used 
in clinics. As there is only one company in Japan that can 
pr pa e allergen extracts, it was thought appropriate to 
select a representative batch of Japanese cedar pollen 
extr ct produced by this company if the extract could be 
confirmed as having adequate quality. Therefore, eight 
batches of cedar pollen extract supplied by this company
were examined as candidates for the standard extract. All 
ba ches supplied were confirmed to have adequate qual-
ity. Therefore, a representative batch was selected as the 
standard extract. For standardization we believe that the 
titer of the standard extract should first be determined by 
the skin prick test and then the titer should be maintained
and managed by in vitro methods in place of the skin test. 
The titration of all allergen extract by the skin test may 
reflect its own biological activity. Furthermore, the unit of 
the titer thus determined is the same for any kind of aller-
gen and any kind of extract of the same concentration 
can be expect d to produce the same degree of reaction
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in any group of patients who are similarly sensitized. 
However, the skin test gives a large burden to patients 
and it is difficult to repeat the test. Therefore, after the titer 
has been determined by the skin test, it is thought best to 
use in vitro methods that will reflect the in vivo reaction. 
The JAU (Japanese allergy unit) was newly created as a 
common unit for all allergens.
 For the calculation of the JAU, a skin test was per-
formed according to the method of the FDA with some 
modifications. Therefore, when other types of allergens 
are standardized in Japan, allergen extracts that have the 
JAU titer and allergen extracts from the USA that have the 
AU titer can be considered to have almost the same 
potency. Although the relative activity determined by in 
vitro methods was consistent between the three types of
cedar extract examined, the relative activity determined 
by the skin test showed some discrepancy (Tables 1, 2). 
This does not necessarily mean that the in vitro estimation 
does not reflect in viva activity but, rather, that in viva 
reactions to the extract are not necessarily linear and 
show individual variations. Batch B is different to batch A,
even though batch B is the dilution of a batch that was 
prepared in a manner similar to batch A. In considering 
this, the results could suggest that in vitro tests reflect the 
real activity more so than do the in vivo tests.
  An error of one-step concentration may easily occur it 
an endpoint is determined by measuring the diameters of 
the wheal and flare. Therefore, it may be necessary to 
determine endpoints as done in the method of the FDA, 
where optimal lines are obtained from the relationship 
between the dilution of the extracts and flare diameters.
 In order to confirm equal activity of an extract with the 
standard extract measurement of Cry i by ELISA is used. 
There are three reasons why this is an appropriate 
method to use. First, total allergen activity can be only 
presented as a relative activity to standard activity when 
the RAST/ELISA inhibition test is used, but it can be 
presented as an absolute concentration of allergenic
protein (μ9/mL) when allergen concentration is mea-
sured. Second, the RAST/ELISA inhibition test requires 
a large amount of patient serum, which could be difficult 
to obtain. Furthermore, when the serum used is changed, 
the results may be affected. However, when ELISA using a 
monoclonal antibody is used, the antibody is perfectly
homogeneous and can be produced in large quantities 
for a long period of time and the method itself is simple 
and has good sensitivity and reproducibility. 
 Third, when comparing Cry j 1 with Cry j 2, antibodies 
to Cry j 2 are difficult to obtain and the number of labo-
ra ories that can measure Cry j 2 are limited. In contrast, 
m ny monoclonal antibodies to Cry j 1 have been pre-
pared12-14 and many laboratories are able to measure 
Cry j 1 at this time. Furthermore, there is no problem with 
regards to reproducibility of results, as clearly demon-
str ted in this study. In the USA, where the method of
measurement of major allergens is well established, as in 
the Amb a of ragweed and the Feld 1 of cat, in vitro tests 
are used, and for many allergens the RAST/ELISA inhibi-
tion test has been changed to the measurement of major 
allerg ns. Of course, the representation of the titer of an 
allergen extract by the concentration of only one kind of
major allergen is the minimum necessary to certify the 
qual ty of the extract. For the purposes of commercial 
production of a standardized cedar pollen extract that is 
of a high quality and has small variations in quality 
between batches, the measurement of not only Cry j 1 but
also Cry j 2 and the total allergenic activity is desirable, 
as is the use of many different tests to maintain and man-
age quality of the extract. 
 T e Allergen Committee is now discussing how best to 
manage the standardized cedar pollen extract and how 
to distribute it to individuals who may wish to obtain it.
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